Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer’s disease
Abstract
Background Alzheimer's disease (AD) is the most prevalent form of dementia. Currently, the most studied biomarkers of AD are cerebrospinal fluid (CSF) amyloid β 1-42, total tau and phosphorylated tau. However, misdiagnosis can exceed 20%. Recently, we found that CSF amyloid β precursor-like protein-1 (APLP1) and neuronal pentraxin receptor (NPTXR) are promising biomarkers of AD. The aim of the present study is to validate CSF APLP1 and NPTXR as biomarkers of AD severity. Methods APLP1 and NPTXR concentrations were measured in the CSF of patients with mild cognitive impairment (MCI) (n = 14), mild AD (n = 21), moderate AD (n = 43) and severe AD (n = 30) using enzyme-linked immunosorbent assays (ELISAs). Results CSF APLP1 and NPTXR were not associated with age or sex. CSF APLP1 was not different between any of the AD severity groups (p = 0.31). CSF NPTXR was significantly different between MCI and mild AD (p = 0.006), mild and moderate AD (p = 0.016), but not between moderate and severe AD (p = 0.36). NPTXR concentration progressively declined from MCI to mild, to moderate and to severe AD patients (p < 0.0001, Kruskal-Wallis test). CSF NPTXR positively correlated with the Mini-Mental Status Examination (MMSE) score (p < 0.001). Conclusions NPTXR concentration in CSF is a promising biomarker of AD severity and could inform treatment success and disease progression in clinical settings.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CSF NPTXR can discriminate between advanced AD stages and MCI (Area under the curve = 0.799).
“Accordingly, CSF NPTXR can discriminate between advanced AD stages and MCI (Area under the curve = 0.799) (Begcevic et al. 2018; Lim et al. 2019).”
From Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration (2022) · cites this paper as Lim et al. 2019
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · see citing works
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980 · see citing works
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925 · see citing works
Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331 · see citing works
NPTX2 and cognitive dysfunction in Alzheimer’s Disease
Xiao, M.-F., Xu, D., Craig, M. T., Pelkey, K. A., Chien, C.-C., Shi, Y., Zhang, J., Resnick, S., Pletnikova, O., Salmon, D., et al. (2017) · eLife · doi:10.7554/elife.23798 · Cited by 316 · see citing works
Biomarkers for the Early Detection and Progression of Alzheimer's Disease
Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0481-z · Cited by 224 · see citing works
Enzymically amplified time-resolved fluorescence immunoassay with terbium chelates
Christopoulos, T. K., & Diamandis, E. P. (1992) · Analytical Chemistry · doi:10.1021/ac00028a004 · Cited by 215 · see citing works
Self-citationCerebrospinal fluid proteomic biomarkers for Alzheimer's disease
Finehout, E. J., Franck, Z., Choe, L. H., Relkin, N. R., & Lee, K. H. (2006) · Annals of Neurology · doi:10.1002/ana.21038 · Cited by 185 · see citing works
Dodds, D. C., Omeis, I. A., Cushman, S. J., Helms, J. A., & Perin, M. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.21488 · Cited by 170 · see citing works
Neuronal pentraxin, a secreted protein with homology to acute phase proteins of the immune system
Schlimgen, A. K., Helms, J. A., Vogel, H. S., & Perin, M. S. (1995) · Neuron · doi:10.1016/0896-6273(95)90308-9 · Cited by 163 · see citing works
Presynaptic neuronal pentraxin receptor organizes excitatory and inhibitory synapses
Lee, S.-J., Wei, M., Zhang, C., Maxeiner, S., Pak, C., Calado Botelho, S., Trotter, J., Sterky, F. H., & Südhof, T. C. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2768-16.2016 · Cited by 146 · see citing works
Yin, G. N., Lee, H. W., Cho, J.-Y., & Suk, K. (2009) · Brain Research · doi:10.1016/j.brainres.2009.01.058 · Cited by 143 · see citing works
Wildsmith, K. R., Schauer, S. P., Smith, A. M., Arnott, D. P., Zhu, Y., Haznedar, J., Kaur, S., Mathews, W. R., & Honigberg, L. A. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-22 · Cited by 140 · see citing works
Collins, M. A., An, J., Hood, B. L., Conrads, T. P., & Bowser, R. P. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00804 · Cited by 98 · see citing works
Begcevic, I., Brinc, D., Brown, M., Martinez-Morillo, E., Goldhardt, O., Grimmer, T., Magdolen, V., Batruch, I., & Diamandis, E. P. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.04.027 · Cited by 81 · see citing works
Self-citationCerebrospinal fluid proteome comparison between multiple sclerosis patients and controls
Kroksveen, A. C., Guldbrandsen, A., Vedeler, C., Myhr, K. M., Opsahl, J. A., & Berven, F. S. (2012) · Acta Neurologica Scandinavica · doi:10.1111/ane.12029 · Cited by 80 · see citing works
Yanagida, K., Okochi, M., Tagami, S., Nakayama, T., Kodama, T. S., Nishitomi, K., Jiang, J., Mori, K., Tatsumi, S., Arai, T., et al. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900026 · Cited by 78 · see citing works
Schilling, S., Mehr, A., Ludewig, S., Stephan, J., Zimmermann, M., August, A., Strecker, P., Körte, M., Koo, E. H., Müller, U., et al. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1875-16.2017 · Cited by 77 · see citing works
Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease
Hu, Y., Hosseini, A., Kauwe, J. S. K., Gross, J., Cairns, N. J., Goate, A., Fagan, A. M., Townsend, R. R., & Holtzman, D. M. (2007) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200600999 · Cited by 75 · see citing works
Hendrickson, R. C., Lee, A. Y. H., Song, Q., Liaw, A. I., Wiener, M., Paweletz, C. P., Seeburger, J. L., Li, J., Meng, F., Deyanova, E. G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135365 · Cited by 68 · see citing works
Shi, M. Y., Movius, J., Dator, R., Aro, P., Zhao, Y., Pan, C., Lin, X., Bammler, T. K., Stewart, T., Zabetian, C. P., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.040576 · Cited by 68 · see citing works
Liquid Biopsy Applications in the Clinic
Chen, D., Xu, T., Wang, S., Chang, H., Yu, T., Zhu, Y., & Chen, J. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00444-8 · Cited by 54 · see citing works
Begcevic, I., Tsolaki, M., Brinc, D., Brown, M., Martinez-Morillo, E., Lazarou, I., Kozori, M., Tagaraki, F., Nenopoulou, S., Gkioka, M., et al. (2018) · F1000Research · doi:10.12688/f1000research.15095.1 · Cited by 51 · see citing works
Self-citationKey Peptides and Proteins in Alzheimer’s Disease
Penke, B., Bogár, F., Paragi, G., Gera, J., & Fülöp, L. (2019) · Current Protein and Peptide Science · doi:10.2174/1389203720666190103123434 · Cited by 50 · see citing works
Amyloid precursor-like protein 1 accumulates in neuritic plaques in Alzheimer's disease
Bayer, T. A., Paliga, K., Weggen, S., Wiestler, O. D., Beyreuther, K., & Multhaup, G. (1997) · Acta Neuropathologica · doi:10.1007/s004010050745 · Cited by 39 · see citing works
APLP1 is endoproteolytically cleaved by γ-secretase without previous ectodomain shedding
Schauenburg, L., Liebsch, F., Eravci, M., Mayer, M., Weise, C., & Multhaup, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-19530-8 · Cited by 36 · see citing works
Ritter, A. R., Cummings, J. L., Nance, C., & Miller, J. B. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.006 · Cited by 18 · see citing works
APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment
Sjödin, S., Andersson, K. K. A., Mercken, M. H., Zetterberg, H., Borghys, H., Blennow, K., & Portelius, E. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0160-z · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Fluid Biomarkers for Synaptic Dysfunction and Loss
Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Biomarker Insights · doi:10.1177/1177271920950319 · Cited by 165 · see citing works
Gómez de San José, N., Massa, F., Halbgebauer, S., Oeckl, P., Steinacker, P., & Otto, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02411-2 · Cited by 112 · see citing works
Liquid Biopsy Applications in the Clinic
Chen, D., Xu, T., Wang, S., Chang, H., Yu, T., Zhu, Y., & Chen, J. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00444-8 · Cited by 54 · see citing works
Barschke, P., Oeckl, P., Steinacker, P., Al Shweiki, M. R., Weishaupt, J. H., Landwehrmeyer, G. B., Anderl-Straub, S., Weydt, P., Diehl-Schmid, J., Danek, A., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322476 · Cited by 45 · see citing works
Lim, B., Sando, S. B., Grøntvedt, G. R., Bråthen, G., & Diamandis, E. P. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.03.013 · Cited by 39 · see citing works
Self-citationA new generation of AD biomarkers: 2019 to 2021
Hawksworth, J. I., Fernández, E., & Gevaert, K. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101654 · Cited by 34 · see citing works
Ivanova, O., Meilán, J. J. G., Martínez‐Sánchez, F., Martínez‐Nicolás, I., Llorente, T. E., & Carcavilla-González, N. (2021) · Computer Speech & Language · doi:10.1016/j.csl.2021.101341 · Cited by 35 · see citing works
Masi, M., Biundo, F., Fiou, A., Racchi, M., Pascale, A., & Buoso, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076639 · Cited by 23 · see citing works
Photoaffinity Probes for the Identification of Sequence-Specific Glycosaminoglycan-Binding Proteins
Joffrin, A. M., & Hsieh‐Wilson, L. C. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c06046 · Cited by 22 · see citing works
Santana, D. A., Bedrat, A., Puga, R., Turecki, G., Mechawar, N., Faria, T. C., Gigek, C., Payão, S., Smith, M., Lemos, B., et al. (2022) · Epigenomics · doi:10.2217/epi-2022-0096 · Cited by 16 · see citing works
Xie, L., Sheehy, R. N., Muneer, A., Xiong, Y., Wrobel, J. A., Zhang, F., Park, K., Velez, J., Liu, J., Luo, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59128-z · Cited by 20 · see citing works
Kulczyńska‐Przybik, A., Dulewicz, M., Doroszkiewicz, J., Borawska, R., Słowik, A., Zetterberg, H., Hanrieder, J., Blennow, K., & Mroczko, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713166 · Cited by 15 · see citing works
Plasma proteomic analysis identifies proteins and pathways related to Alzheimer's risk
Huang, Y.-N., Liu, S., Park, T., Chaudhuri, S., Kuchenbecker, L. A., Carrasquillo, M. M., Ertekin‐Taner, N., Bice, P. J., Zetterberg, H., Blennow, K., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70579 · Cited by 13 · see citing works
Saunders, T. S., Gadd, D. A., Spires‐Jones, T. L., King, D., Ritchie, C. W., & Terrera, G. M. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15656 · Cited by 12 · see citing works
Zhu, S., Bäckström, D., Forsgren, L., & Trupp, M. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-213031 · Cited by 10 · see citing works
Lim, B., Fowler, C., Li, Q.-X., Rowe, C., Dhiman, K., Gupta, V. B., Masters, C. L., Doecke, J. D., Martins, R. N., Collins, S., et al. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135078 · Cited by 10 · see citing works
Self-citationArias, C. C. W. P., Silbern, I., Gomes, L. C., Wartmann, H., Dambeck, V., Fanz, J., Neuenroth, L., Bähr, M., Outeiro, T. F., Bonn, S., et al. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15924 · Cited by 9 · see citing works
Gómez, G., Shi, L., Fohner, A. E., Chen, J., Yang, Y., Fornage, M., Duggan, M. R., Peng, Z., Daya, G. N., Tin, A., et al. (2024) · medRxiv · doi:10.1101/2024.10.07.24314972 · Cited by 7 · see citing works
Seo, D., Do, A. N., Heo, G., Kwon, J., Song, S., Apio, C., Lee, C. M., Timsina, J., Gong, K., Chen, Y., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00971-6 · Cited by 10 · see citing works
Huang, X.-F., Mingxia, X., Chen, Y.-F., Lin, Y.-Q., Lin, Y., & Wang, F. (2023) · World Journal of Psychiatry · doi:10.5498/wjp.v13.i10.714 · Cited by 3 · see citing works
Dai, L., Kirsebom, B., Wang, C., Zhang, M., Wang, Q., Ni, M., González‐Ortiz, F., Blennow, K., Shi, J., Fladby, T., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70472-6 · Cited by 3 · see citing works
Analysing and Evaluating Complementarity of Multi-Modal Data Fusion in AD Diagnosis
Chen, Z., Nan, F., Yang, Y., Wang, J., & Yang, P. (2022) · International Conference on Mobility, Sensing and Networking (MSN) · doi:10.1109/msn57253.2022.00135 · Cited by 3 · see citing works
Three Neurodegenerative Diseases: A Single Hope
Youssef, S. H., Atalah, H. N., Badawy, M. T., El‐Fawal, H. A. N., & Salama, M. (2024) · Springer eBooks · doi:10.1007/978-981-99-7557-0_3 · Cited by 1 · see citing works
Three Neurodegenerative Diseases: A Single Hope
Youssef, S. H., Atalah, H. N., Badawy, M. T., El‐Fawal, H. A. N., & Salama, M. (2023) · Springer eBooks · doi:10.1007/978-981-19-3949-5_3-1
Diagnostic and progression biomarkers in cerebrospinal fluid of Alzheimer’s disease patients
Chatanaka, M. K., Prassas, I., & Diamandis, E. P. (2024) · BMC Medicine · doi:10.1186/s12916-024-03270-w
Self-citation
- Authors
- Lim, B., Tsolaki, M., Soosaipillai, A., Brown, M., Zilakaki, M., Tagaraki, F., Fotiou, D., Koutsouraki, E., Grosi, E., Prassas, I., & Diamandis, E. P.
- Affiliations
- University of Toronto (CA)
- Aristotle University of Thessaloniki (GR)
- Mount Sinai Hospital (CA)
- Fred Hutch Cancer Center (US)
- 1st Department of Neurology, Medical School , Aristotle University of Thessaloniki , Thessaloniki , Greece
- Corresponding author
- Tsolaki, Magda
- Diamandis, Eleftherios P.
- ORCID
- Venue
- Clinical Chemistry and Laboratory Medicine (CCLM)
- Publisher
- Walter de Gruyter GmbH
- Published
- 2019-08-15
- Volume
- 57
- Issue
- 12
- Pages
- 1875-1881
- ISSN
- 1434-6621 (ISSN-L)
- 1437-4331
- OpenAlex
- W2968734721
- Cited by
- 25
- References
- 29
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 5 · 2022: 5 · 2021: 2 · 2020: 6
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Chemistry and Laboratory Medicine (CCLM) (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, liquid biopsy, cerebrospinal fluid biomarkers, disease progression, mild cognitive impairment, disease severity, Mini-Mental State Examination
- MeSH terms
- Liquid Biopsy, Pentraxins, Aged, Alzheimer Disease, C-Reactive Protein, Female, Greece, Humans, Male, Middle Aged, Nerve Tissue Proteins, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, tau Proteins, Disease Progression, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
